Immunovia AB (publ)
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Market Cap & Net Worth: Immunovia AB (publ) (IMMVF)
Immunovia AB (publ) (PINK:IMMVF) has a market capitalization of $49.64 Million ($49.64 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #26314 globally and #8904 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunovia AB (publ)'s stock price $0.07 by its total outstanding shares 672666892 (672.67 Million).
Immunovia AB (publ) Market Cap History: 2019 to 2025
Immunovia AB (publ)'s market capitalization history from 2019 to 2025. Data shows change from $12.21 Billion to $49.64 Million (-61.32% CAGR).
Immunovia AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunovia AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
72.65x
Immunovia AB (publ)'s market cap is 72.65 times its annual revenue
0.68x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $12.21 Billion | $356.00K | -$114.52 Million | 34294.67x | N/A |
| 2020 | $12.24 Billion | $362.00K | -$146.03 Million | 33819.16x | N/A |
| 2021 | $4.98 Billion | $844.00K | -$155.97 Million | 5897.79x | N/A |
| 2022 | $2.12 Billion | $1.15 Million | -$168.09 Million | 1853.51x | N/A |
| 2023 | $114.35 Million | $1.57 Million | -$309.44 Million | 72.61x | N/A |
| 2024 | $49.64 Million | $931.00K | -$76.54 Million | 53.32x | N/A |
| 2025 | $49.64 Million | $683.28K | -$145.55 Million | 72.65x | N/A |
Competitor Companies of IMMVF by Market Capitalization
Companies near Immunovia AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to Immunovia AB (publ) by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #93 globally with a market cap of $174.19 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #150 globally with a market cap of $120.45 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #468 globally with a market cap of $45.61 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #507 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #93 | Thermo Fisher Scientific Inc | NYSE:TMO | $174.19 Billion | $464.69 |
| #150 | Danaher Corporation | NYSE:DHR | $120.45 Billion | $191.50 |
| #468 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.61 Billion | $577.12 |
| #507 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Immunovia AB (publ) Historical Marketcap From 2019 to 2025
Between 2019 and today, Immunovia AB (publ)'s market cap moved from $12.21 Billion to $ 49.64 Million, with a yearly change of -61.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $49.64 Million | 0.00% |
| 2024 | $49.64 Million | -56.59% |
| 2023 | $114.35 Million | -94.61% |
| 2022 | $2.12 Billion | -57.36% |
| 2021 | $4.98 Billion | -59.34% |
| 2020 | $12.24 Billion | +0.28% |
| 2019 | $12.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Immunovia AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.64 Million USD |
| MoneyControl | $49.64 Million USD |
| MarketWatch | $49.64 Million USD |
| marketcap.company | $49.64 Million USD |
| Reuters | $49.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.